Bli medlem
Bli medlem

Du är här

2020-04-24

Xvivo Perfusion: XVIVO appoints a new IP manager and a new Medical Director

Anne-Li Sigvardsson, MSc has been appointed Chief Intellectual
Property Officer (CIPO). Anne-Li is responsible for the company's IP
portfolio and has developed XVIVO's patent portfolio for PrimECC and
Perfadex Plus, among other products. Andreas Wallinder, MD, PhD has
been appointed Chief Medical Officer (CMO). Andreas is the indication
leader for the company's heart preservation development and also
clinically responsible within the company.

Anne-Li Sigvardsson has a MSc in chemical engineering and has worked
with research and development in the medical technology field for
more than 20 years, and with XVIVO products since 2004. Previously,
she has also worked with global marketing and sales, an experience
that gave a good understanding for developing intellectual property
that is relevant and useful in the market. Anne-Li is responsible for
the company's IP portfolio.

Andreas Wallinder has been employed at XVIVO for 6 months. He
specialized in thoracic surgery and has performed research and his
PhD in the field of EVLP (Ex Vivo Lung Perfusion) and lung
transplantation. During his 16 years at Sahlgrenska University
Hospital, as well as Alfred Health in Melbourne, Andreas has
performed both lung transplants and heart transplants. Andreas is the
indication leader for the company's heart preservation development
and also clinically responsible within the company.

"One of XVIVO's strategic cornerstones is to recruit employees with
high competence, an innovation mindset and strong a faith in the
company's vision - that no one should die waiting for an organ. These
employees are another two very good examples of this and I am proud
that we can continue to attract and retain highly qualified
employees.," says Magnus Nilsson, CEO of XVIVO Perfusion.

April 24, 2020

Gothenburg

XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159,
christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, +46 31 788 2150,
magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion's business, please refer to
the company's website, www.xvivoperfusion.com

The information was submitted for publication, through the agency of
the contact person set out above, at 3:40 am CET on April 24, 2020.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in Lund, Sweden and one office in Denver, the USA. The XVIVO share is
listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More
information can be found on the website www.xvivoperfusion.com.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
-----------------------------------------------------------
https://news.cision.com/se/xvivo-perfusion/r/xvivo-appoints-a-new-ip-man...
https://mb.cision.com/Main/4567/3096533/1235708.pdf

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.